In the melanoma TCGA dataset, the GREB1 expression levels did not differ between patients with and without BRAF mutation, and even in WT BRAF patients, who would be expected to be ineffective on BRAF inhibitors, the GREB1 high group had a poor prognosis (Supplementary Fig. S12A, B). This evidence concerns the gene BRAF and melanoma.